SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news

 

 

Boehringer Ingelheim taps Philogen DNA-encoded chemistry tech

Melissa Fassbender

By Melissa Fassbender

31-Jul-2017
Last updated on 31-Jul-2017 at 19:38 GMT2017-07-31T19:38:19Z

(Image: iStock/Antiv3D)
(Image: iStock/Antiv3D)

Boehringer Ingelheim and Philogen have signed a multi-target research agreement to discover and optimize new small molecule therapeutics for unmet medical needs.

The collaboration leverages Philogen’s DNA-Encoded Chemistry technology and Encoded Self-Assembling Chemical (ESAC) platform.

According to the Swiss-Italian company, the complementary discovery technologies enable the screening of up to billions of small molecules. The technology also optimizes hit compounds in a “fully automatic, DNA-tagged, fragment-based drug discovery manner.”

Philogen DNA-Encoded libraries are extremely pure and based on smart design in order to provide a rich diversity without the need to work with huge and poorly manageable libraries. Moreover, ESAC technology allows a very fast and efficient way to optimize initial hit compounds and perform lead expansion,” a Philogen representative told Outsourcing-Pharma.com.

Philogen is delighted to have expanded its ongoing collaborations with Boehringer Ingelheim beyond the area of biologics,” they added.

The companies have previously worked together as part of a collaboration to explore investigate treatment approaches for Acute Myeloid Leukemia (AML).

Financial details of the agreement were not released.

Related suppliers

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...